This partnership expands access to advanced genomic testing.
SAO PAULO, Dec. 19, 2024 — MGI Tech Co., Ltd. (“MGI”), a life sciences innovator, has partnered with Sabin Group, a major Brazilian diagnostics laboratory, to enhance health diagnostics using genetic sequencing. This collaboration expands Sabin’s test offerings and broadens Brazilian access to innovative genomics testing.
Sabin Group, operating across fifteen Brazilian states for 40 years, serves over 7 million customers annually, providing clinical analysis, diagnostic imaging, vaccinations, and examinations.
The MGI-Sabin partnership is crucial for advancing personalized medicine in Brazil. Expanded access to advanced genetic sequencing enables more precise diagnoses and personalized treatments based on individual genetic profiles. This improves clinical outcomes and promotes preventative, efficient healthcare, transforming medical practices.
“Combining our advanced technology with Sabin’s extensive network and expertise creates a synergy transforming Brazilian healthcare. Sabin’s strong presence, coupled with our genetic sequencing solutions, provides broader access to accurate diagnostics. This partnership elevates care standards and promotes more personalized and efficient medicine,” explains Carlos Carpio, MGI Latin America’s Senior Commercial Director and Brazil General Manager.
“MGI’s sequencing technology significantly advanced our genomic operations. Expanded sequencing capacity allows for more comprehensive and precise analyses, improving diagnostics and driving personalized medicine. This partnership seamlessly integrated, offering efficient, innovative solutions and fostering mutual growth. The results are reliable and high-quality, reflecting our commitment to patient care and leveraging genomics advancements,” says Rafael Jácomo, Technical Director.
This collaboration makes cutting-edge genomic testing more widely available. Identifying genetic predispositions and enabling precise diagnoses facilitates effective, personalized treatments, positively impacting public health and reducing healthcare costs.
Sabin implemented MGI’s DNBSEQ-G400 genomic sequencer (for large- and medium-scale sequencing) and MGISP-100 automated library preparation system. The DNBSEQ-G400 increased genomic tests by 78%, significantly enhancing diagnostic capabilities. The MGISP-100’s automation—processing samples in batches, eliminating repetitive tasks, increasing library preparation stability, and reducing costs—further amplifies this growth, driving personalized medicine advancements.
High costs often limit access to advanced medical technologies. The MGI-Sabin partnership is a significant step forward, enabling broader access to genomic testing and precision medicine benefits for Brazilians.
MGI opened a Customer Experience Center (CEC) in Brazil this April to strengthen genomic sequencing infrastructure and scientific development.
“Genetic sequencing is essential for precision medicine. Advanced technologies make personalized medicine a reality, boosting healthcare development and improving patient quality of life in the coming years,” concludes Carlos Carpio.
SOURCE MGI TECH